Navigation Links
Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Date:11/7/2007

e Ziplex System. There is a great deal of interest in focused content - and there are few competitive alternatives. We expect to have a variety of condition- or pathway-specific Signature Chips that will be available both as catalog products and through Xceed's Expression Services. The Metabolic Signature Chip, designed to investigate differential expression associated with diseases of the metabolic system (e.g. muscle disorders, obesity, and other metabolic diseases), is available today. In addition, Xceed now offers the Breast and Colon Cancer Signature Chips. We have a number of other Signature Chips in development for inflammation and for a range of cancers, including prostate, lung, and melanoma. We are actively pursuing licensing arrangements with strategic partners to add other signatures to our pipeline."

The list price for the Ziplex Automated Workstation, which automates the hybridization, imaging, quantitation, and quality control, is $85,000 USD. The TipChip consumable that contains assay-specific content can cost as little as $120 USD per TipChip. (The price will vary based on content.) As part of the AMP launch, Xceed is offering special promotional pricing for early adopters.

Technical Topics Workshop

Xceed is also sponsoring a Technical Topics Workshop at the conference: Translational Research of Gene-Expression Assays to the Ziplex Automated Workstation by David Englert, PhD. Time: 1 to 2 pm, Wed, Nov 7, 2007, Hyatt Regency Century Plaza Hotel Constellation Room A.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex(R) System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, and pre- configured arrays. Xceed is also developing multiplexed genomic t
'/>"/>

SOURCE Xceed Molecular
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AdvaMed 2007 Exceeds Attendance Expectations With More Than 1,100 Participants from 35 States and 25 Countries
2. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
3. A new molecular zip code, and a new drug target for Huntingtons disease
4. New knock-out gene model provides molecular clues to breast cancer
5. Molecular probe paints cancer cells in living animals, Stanford researchers find
6. Story ideas from molecular & cellular proteomics
7. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
10. Molecular profiling can accurately predict survival in colon cancer patients
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 2Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 3Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 4Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 5Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 6Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 7Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 8Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 9